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A commentary on
Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation 
in Kidney Transplantation
by Schroder PM, Ezekian B, Ford M, Knechtle SJ, Kwun J. Front Immunol (2017) 8:1615. doi: 10.3389/
fimmu.2017.01615
The commentary by Schroder et  al. on our report “Belatacept Does Not Inhibit Follicular T Cell-
Dependent B-Cell Differentiation in Kidney Transplantation,” challenges our findings and conclusions 
by questioning the methodology, definitions and interpretation of the results (1). We appreciate the 
comments and acknowledge that discussion about the mechanistic basis of the rejection response 
will advance our understanding of this process and may improve outcomes after transplantation, the 
goal of the transplant community.
After transplantation, a cellular infiltrate in the transplanted organ consisting of both T and B cells 
is a hallmark of the anti-donor rejection response. In our study, we questioned whether a subset of 
T cells, the CXCR5+CD4+ T follicular (Tfh) cells, provides help to B cells in immunosuppressed 
kidney transplant patients (2–4). We examined Tfh–B  cell interactions in patients treated with 
either belatacept- or tacrolimus-based immunosuppression [a CTLA4-immunoglobulin (Ig) and an 
inhibitor of the CD28-CD80/86 pathway, and an inhibitor of the calcineurin pathway, respectively] 
(2, 4). The capacity of Tfh cells to provide help to B cells depends on costimulatory molecules such 
as ICOS, PD-1, CD28, and the cytokine IL-21 (3).
In brief, three arguments were put forward as to why we should have been more cautious in our 
conclusions (1). The first argument is that we investigated the isolated effects of belatacept and that 
our study lacked unmodified controls; second, that Tfh–B cell interactions were studied in peripheral 
blood samples; and third, the definition we used to define Tfh cells.
We believe that Schroder et al. possibly overlooked some of the details of our study. As summa-
rized in Figure 1, different comparisons were made, including the unmodified immune response (2). 
We agree that isolated immunosuppressive drug effect studies may not reflect the in vivo situation 
in patients and for this reason we included data labeled “in vivo drug studies.” These demonstrated 
the in vivo effect of the immunosuppressive treatment in our patient group. The capacity for Tfh cell 
generation, activation, and the ability to mediate B cell differentiation and Ig production, was tested 
in patient samples rechallenged in vitro with donor antigen. These experiments demonstrated that 
peripheral Tfh cells remained functional. In this respect, our opinion differs from that of Schroder 
et al., who suggest a long-lasting effect of belatacept and tacrolimus on isolated Tfh and B cells (1). 
To be certain that the effect of drugs can be measured at all in our system, belatacept and tacrolimus 
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were added to the interaction of donor antigen Tfh–B  cells, 
which resulted in a median inhibition of 33 and 55%, respectively 
[in vitro drug experiments; Figure 5 (2)]. These findings led us 
to the conclusion that the immunosuppressive drugs studied—
including belatacept—have a limited effect. We are of course aware 
that combination therapy, including mycophenolate mofetil and 
steroids, may influence Tfh–B cell cross talk in vivo. The unique 
setting of our study, i.e., donor antigen-specific activation of the 
Tfh–B  cell interaction in peripheral blood cell samples from 
kidney transplant patients, can result in different outcomes from 
isolated Tfh cell studies [Figure S2 in Supplementary Material (2)] 
that certainly do not reflect the real-world situation in human 
transplant recipients, let alone from studies based on cells from 
healthy blood bank donors or in vitro generated Tfh cells (1, 2). 
A study by Badell et al. has reported clear-cut effects of CTLA4-Ig 
in the prevention of Tfh cell-mediated humoral immune activity 
in a murine skin transplant model (2, 5). As acknowledged by 
Ford [co-author of Schroder et al. (1)], findings from transplant 
models using inbred animals are difficult to extrapolate to 
transplantation in patients with an adult immune system (6). 
Substantial differences exist in terms of the basal immune state of 
these mice in comparison to patients which can contribute to the 
findings in studies (2, 5–7).
The second limitation ascribed to our study is that a study of 
the secondary lymphoid organs, where most Tfh–B cell interac-
tions occur, is lacking (8). This reflects the conventional opinion 
that immune responses occur in these organs. In transplantation, 
however, Tfh–B cell interactions also occur in the transplanted 
organ itself. We demonstrated the presence of Bcl6+ (Tfh-
transcription factor) and IL-21+ T cells in kidney allograft biopsies 
that colocalized with B cells and Igs during rejection (9, 10). Our 
biopsy studies further revealed that in belatacept treated patients 
the target molecule, CD86, was still expressed by mononuclear 
cells, which can be explained by the small distribution volume of 
belatacept (11, 12). We agree that unraveling the function of Tfh 
and B cells residing in secondary lymphoid organs will provide 
mechanistic insights into the pathways involved in alloreactiv-
ity, which will, in turn, help us to develop better pharmacologic 
inhibitors to control cellular and antibody-mediated allograft 
rejection (13, 14). However, because of ethical considerations, 
this can only be studied in animal transplant models.
Finally, with regard to the comment about the definition of 
peripheral Tfh cells: the role of Tfh cell humoral immunity has 
been recognized in the field of human immunology, where it 
has been shown that circulating CXCR5+CD4+ T  cells are the 
counterparts of germinal center Tfh cells (3, 15). These Tfh cells 
may differ from lymph node Tfh cells since peripheral Tfh cells 
express ICOS and PD-1 at low levels. However, in an allogeneic 
setting circulating CXCR5+CD4+ T  cells have the capacity to 
provide help to B cells (16). Nevertheless, the definition of Tfh 
cells by CXCR5 is only an approximation, and some fine tuning 
is required.
Over the past few years, we have made major progress in under-
standing how immunosuppressive drugs act in patients through 
the study of blood and biopsy material. In belatacept-treated 
patients, the incomplete blockade of costimulatory pathways and 
redundancy in the immune system may contribute to the appar-
ent lack of efficacy when tested in vitro and in patients (2, 4, 17). 
Direct translation of findings in different models is difficult—if 
not impossible—because the test model influences the outcome 
and consequently, the conclusions. We have to work in collabora-
tion to find improved models that will, eventually, help us find 
solutions for the current challenges such as effective treatment of 
antibody-mediated rejection.
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